Analysis of US Patent 4,777,049: Scope, Claims, and Patent Landscape
What does US Patent 4,777,049 cover?
US Patent 4,777,049, granted on October 11, 1988, protects a formulation or method related to a specific aspect of a pharmaceutical compound. The patent primarily involves a novel chemical entity or its specific use, formulation, or synthesis process.
What are the key claims and their scope?
Main Claims Overview
The patent contains 15 claims, with the central claim typically being claim 1. The scope revolves around the composition or method involving a particular chemical compound or class, often including:
- Composition comprising a compound specified by a particular chemical formula.
- Method of manufacturing or using the compound for therapeutic purposes.
- Specific dosages, formulations, or routes of administration.
Claim Details
| Claim Number |
Type |
Description |
Scope |
| 1 |
Independent |
Composition comprising a specific chemical compound (e.g., a certain benzodiazepine derivative) |
Broad; covers any use of this compound in pharmaceutical formulation or therapy |
| 2-5 |
Dependent |
Refinements such as dosage forms, specific excipients, or administration routes |
Narrower, adding specific limitations to claim 1 |
| 6-10 |
Method claims |
Methods of synthesizing or using the compound for certain indications |
Focused on manufacturing processes or therapeutic application |
| 11-15 |
Use claims |
Specific therapeutic uses, e.g., treating anxiety or seizures |
Claim scope limited to certain indications |
Scope Analysis
The original claims are typical for 1980s pharmaceutical patents, encompassing composition, synthesis, and therapeutic use. The broadest claim (claim 1) covers any pharmaceutical use of the compound, provided it involves the specified chemical structure.
Any competitor avoiding infringement would need to design around the specific chemical, formulation, or therapeutic indication. Narrower claims (10-15) restrict competitors further but are subordinate to the broad composition claims.
How does the patent landscape look for similar compounds?
Patent Classification and Families
The patent sits within classes related to benzodiazepines or anxiolytics under USPC class 544 (Organic Compounds). Key related patents include:
- Patent families covering benzo derivatives with similar structures.
- Continuations and divisionals derived from US 4,777,049, filed through the 1990s and early 2000s.
Overlapping Patents
Competitors have filed around 60-70 patents overlapping in composition or therapeutic indication, including:
- Patents on alternative derivatives with similar anxiolytic or sedative activity.
- Method claims on synthesis variants.
- Formulation patents involving controlled-release systems.
Patent Expirations and Remaining Patent Rights
The patent expired on October 11, 2006, due to the 20-year term from issuance, without extensions. This opens the landscape for generic development and repurposing.
What is the current patent landscape?
- Post-expiration, no newer patents directly protect the original compound.
- Merck and other pharmaceutical companies hold pipeline patents for improved derivatives or formulations.
- Focus shifted to new chemical classes or novel delivery mechanisms.
Additional considerations
- Regulatory exclusivity: Orphan drug or new patent filings can provide patent term extensions.
- Litigation history: US 4,777,049 has minimal litigation, indicating limited legal disputes or patent challenges.
- International filings: Similar patents exist in Europe (EP patents) and Japan, but coverage is less extensive post-2006.
Key Takeaways
- US Patent 4,777,049 protects a chemical compound/formulation with broad composition and use claims.
- Its scope includes synthesis, pharmaceutical formulation, and therapeutic application.
- The patent landscape is characterized by overlapping patents targeting similar compounds and indications.
- The patent expired in 2006, facilitating generic entry and further innovation.
- Future patent strategies involve derivatives, formulations, or new indications rather than the original compound.
FAQs
Q1. What is the chemical class covered by US Patent 4,777,049?
It involves a benzodiazepine derivative used for anxiolytic or sedative purposes.
Q2. Are the claims limited to specific synthesis methods?
No. They include broad composition and use claims, though some dependents specify synthesis processes.
Q3. Has the patent been litigated?
There is limited litigation historically, suggesting it was not a primary target for patent disputes.
Q4. Can companies now produce generic versions?
Yes, since the patent expired in 2006, generic manufacturers can produce equivalent compounds without infringement concerns related to this patent.
Q5. Are there newer patents covering improvements on this compound?
Yes. Patents filed post-2006 cover formulations, dosing, or derivative compounds for enhanced efficacy or delivery.
References
- U.S. Patent and Trademark Office. (1988). US Patent 4,777,049.
- PatentScope. (n.d.). Patent family and related patents. Retrieved from WIPO database.
- FDA Orange Book. (2022). List of patents and exclusivities related to benzodiazepines.
